Antibody Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
72
NCT06994676
A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 16, 2025
Completion: Jun 30, 2027
Loading map...